| abstract |
The present invention relates to methods and compositions designed for the prevention, reduction, treatment or management of ischemia-reperfusion injury. The methods of the invention comprise the administration of an effective amount of a therapeutic formulation containing one or more active compounds in a formulation which specifically decreases or inhibits the activity of and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and/or monocytes. In preferred embodiments, the active compound is a bisphosphonate. The invention also provides pharmaceutical compositions of therapeutic formulations for administration to subjects currently suffering from, having recently suffered, or at risk of suffering from an ischemia-reperfusion injury. |